The management of hereditary transthyretin-mediated amyloidosis (hATTR) is important in the medical community, as patients suffer from serious associated symptoms, such as polyneuropathy, which calls for safe and efficacious agents to help slow the progression of the disease. This activity covers the proper use of inotersen contributes to the management of subsequent disease manifestations, including the importance of utilizing such targeted therapy, which, in turn, augments the patient treatment strategy.
Copyright © 2024, StatPearls Publishing LLC.